- Kentucky hospital adds inpatient MyChart platform
- 1 orthopedic surgeon on noncompetes, ASC equity deals and physician mobility
- 5 ASC leaders to watch
- New York hospital to add psychiatric emergency program
- How Sarasota Memorial unlocked 80+ inpatient beds daily without new construction
- FDA disputes estrogen patch shortage concerns
- U of Missouri opens $54.8M autism care facility
- What’s stopping pharmacists from practicing at the top of their license?
- Trump Planning to Fire FDA Commissioner Marty Makary
- Trump Planning to Fire FDA Commissioner Marty Makary
- Boston Scientific recalls pacemakers after 4 deaths, 2,500 injuries
- Accelerating priorities through co-designed precision quality improvement
- Rare bile duct cancer drug earns FDA approval
- CMS cuts funding for Texas psychiatric hospital
- HHS launches maternal health resource website
- FDA issues guidance for safe drug use during pregnancy
- Why new dentists must rethink private practice
- The Hidden Design Flaw in Medical Device Service Technology
- The Hidden Design Flaw in Medical Device Service Technology
- An Endovascular Approach to Neurological Diseases Can Shift the Treatment Paradigm
- An Endovascular Approach to Neurological Diseases Can Shift the Treatment Paradigm
- Maine ophthalmology practice to close
- Carle Health approves Illinois outpatient expansion
- Munson Healthcare to open Michigan ASC
- U of Utah physician earns liver disease research grant
- Why Gen AI is a Win for MedTech: And, How to Unlock its Potential with the Right Policies
- Why Gen AI is a Win for MedTech: And, How to Unlock its Potential with the Right Policies
- Could autism care benefit from more therapy choices?
- The Medical Device Cybersecurity Gap Hiding in Plain Sight
- The Medical Device Cybersecurity Gap Hiding in Plain Sight
- CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion
- Older Adults Have Fewer Regrets, Study Says
- Why Doctors Are Quitting At An Earlier Age
- Healthcare bankruptcies up 33% in Q1 2026: report
- Sharper Brains May Face Higher Depression Relapse Risk, Study Finds
- Nighttime Heat Waves Increase Asthma Risk
- Partner's bispecific Bizengri nabs FDA national priority nod in rare bile duct cancer
- Daiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan
- That Discount At The Pharmacy Counter May Pack Hidden Costs
- As Ranks of Uninsured Grow, Minnesota’s Hospitals Are Among Least Charitable in Nation
- Watch: 8 Health Insurance Terms You Should Know
- OVID Health hires Edelman alum Davide Scalenghe to boost its international footprint
- Maintaining trust in medical AI: Monitoring and managing model lifecycle
- Maintaining trust in medical AI: Monitoring and managing model lifecycle
- Eli Lilly shoots for health in new Caitlin Clark ad campaign
- Omada Health posts 42% revenue jump in Q1, joins Eli Lilly employer weight loss program
- Journalists Shed Light on Deadly Hantavirus Outbreak and a Crisis in the Nation’s ERs
- Is the horizon still bright for orthodontists?
- The Make America Healthy Again Movement Comes for Hospital Food
- Why Tenet’s CEO says ASCs keep choosing USPI
- Hospitals embrace rapid opioid treatment in fentanyl era: Study
- Texas systems open 200-bed behavioral health center
- Lone Peak Dental Group acquires Arizona practice
- Inside Northwestern Medicine’s battle against surgeon burnout
- Tennessee optometrist pleads guilty to $6.9M Medicare fraud
- Surgery Partners doubles down on orthopedics, robotics as total joint growth hits 14.6%
- 3 PDS Health headlines to know in 1 week
- Remarks at the Conference on Financial Market Regulation
- Dad Jokes: Remarks at the 13th Annual Conference on Financial Markets Regulation
- Maine behavioral health provider cites industry pressures in merger
- Dentists opening practices in 1 month
- The Aspen Group names new chief commercial officer
- RFK Jr. Launches Plan To Curb Antidepressant 'Overprescription'
- Georgia mental health provider adds after-hours outpatient program
- AI-augmented behavioral health provider Theris launches out of stealth
- As new tech, AI sweeps the marketing world, Eversana Intouch’s new CEO is ‘comfortable in the gray’
- Sanford Health unveils deal to integrate Minnesota-area North Memorial Health, invest $600M
- UPDATED—Trump plans to fire FDA chief Marty Makary: report
- UPDATED—Trump plans to fire FDA chief Marty Makary: report
- Oregon governor signs behavioral health workforce expansion bills amid shortage
- Remarks at the Special Competitive Studies Project AI+ Expo
- Lawmakers, former FDA leaders and more rally behind mifepristone as Supreme Court weighs telemedicine access to abortion pill
- 5 DSOs making headlines
- Plant-Based Foods May Help Lower Risk of High Blood Pressure
- The ACA exchanges dominated Q1 earnings calls. Here's what payer, health system execs had to say
- Integrated CDO capabilities reduce early development complexity
- Targeted Protein Degradation and Novel Modalities: Getting on the Frontline
- Gilead cranks up Yeztugo first-year sales forecast to $1B on 'unprecedented launch trajectory'
- Workplace safety is a top priority for 93% of healthcare leaders: Axon survey
- Capricor Therapeutics files breach-of-contract lawsuit against US partner NS Pharma
- Op-ed: It's time to make more strategic bets on AI in healthcare
- Daiichi Sankyo takes $610M profit hit linked to ADC manufacturing overbuild
- Super Shoes Might Increase Risk Of Running Injuries, Study Says
- TV, Movies Offer Flawed Depictions Of Autism, Add To Delayed Diagnosis, Study Says
- Opioid OD Survivors Have Triple Rate Of Repeat Overdoses Than Previously Estimated
- Revisiting Pharma’s tariff reality
- A New Medicare Option For Weight Loss Drugs: What Older Americans Should Know
- Exposure Therapy Can Successfully Ease Peanut Allergies
- In California Governor Race, Single-Payer Is a Litmus Test. There’s Still No Way To Pay for It.
- Listen: A Federal Agency Is After Workers’ Health Data, and Critics Are Alarmed
- AbbVie’s Skyrizi beats out J&J’s Tremfya in April drug ad spending leaderboard
- Johnson & Johnson launches ‘Generation Fine’ depression project
- Pre-launch efforts linked to lasting drug awareness edge: report
- GSK tees up a Modern Family for meningitis messaging
- NYC invests $12M in overdose recovery workforce
- Aspen Dental to pay $2M to settle allegations of violating corporate dentistry laws
- Texas dental practice relocates into 6K-square-foot facility
- Medit launches global orthodontics division, acquires California training institute
- Cruise Ship Hantavirus Outbreak Kills 3 as WHO Says Risk Is Low
- How policy, reimbursement incentives, could help healthcare address its climate footprint
- Remarks at the 13th Annual Conference on Financial Market Regulation
- 5 best practices for financially integrating behavioral health
- Fierce Pharma Asia—Summit’s surprise interim trial miss; UCB’s $2B Candid buy; J&J’s CAR-T cuts
- Amazon Pharmacy to offer home delivery for Novo Nordisk's Ozempic pill
- Staffing firm Cross Country Healthcare to be acquired by Knox Lane for $437M
- Clover Health's MA membership grows 51% year-over-year
- New Study Suggests The Brain Can Continue Learning While In An Unconscious State
- Health Tech Weekly Rundown: Tether rolls out medical AI for phones, wearables; Medaptus launches operational ‘command center’
- Pennsylvania sues Character.ai over AI chatbot allegedly presenting itself as licensed medical professional
- Angelini finds Catalyst for its US growth ambitions with $4.1B buyout
- FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?
- Every 1,000 Steps After Surgery Cuts Complication Risk, Study Finds
- Bullying and Politics Fuel Suicide Risk for LGBTQ+ Teens and Young Adults, Survey Finds
- Head Impacts May Disrupt Gut Health Even Without Concussion
- Class of Migraine Drug, CGRP Inhibitors, Has Added Benefit: Reduced Glaucoma Risk
- States Eye Aid to Prop Up Distressed Hospitals Amid Federal Medicaid Cuts
- Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up.
- That Discount at the Pharmacy Counter May Pack Hidden Costs
- Hims & Hers debuts its first AI care agent to interpret biomarker lab results
- Oscar Health's profit hits $679M, membership rises in Q1
- Joint Commission, NACHC partner on training, new accreditation for community health centers
- Ardent Health touts outpatient growth, checked labor spend during hectic Q1
- FDA Authorizes Fruit-Flavored Vapes for Adults
- Nearly 8 in 10 employers say GLP-1 coverage drives up benefit costs: Business Group on Health
- Edibles + Alcohol Combo Poses Driving Risks Missed by Sobriety Tests
- Leapfrog Group's latest safety grades have far fewer low scores since removal of non-participating hospitals
- VR Training Helps Autistic People Navigate Police Encounters
- Weight Loss Surgeries Fall More Than 20% As Patients Turn To GLP-1 Meds, Experts Say
- Amwell boasts higher than expected renewals, retention despite Q1 revenue decline
- First Psych Ward Stay Signals Long-Term Mental Health Struggles For Nearly All Patients
- Why Melatonin Shouldn't Be A Bedtime Go-To For Kids
- Children Living Near Gas Stations Have Higher Cancer Risk, Study Finds
- The timing is right for psychedelics manufacturer Optimi Health's IPO
- HHS' Healthy Food Agenda Puts Hospitals On Notice About Patients' Meals
- Trump’s Drug Strategy Aims To Bolster Addiction Services — Despite Gutting of Government Support
- A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know
- Inside the gaps in fertility and surrogacy systems
- CVS execs say company on track to meet MA margin goals by 2028
- Facilitating Access to Trump Accounts
- Fixing Failures to Communicate
- Supreme Court Issues Stay, Keeping Abortion Pill Mifepristone Available by Mail For Now
- Statement on Proposing Release for Semiannual Reporting
- Quarterly Questions: Statement on the Proposed Amendments to Allow Semiannual Reporting
- Statement on Proposing Semiannual Reporting
- Newer Migraine Drugs Reduce Headache Days With Fewer Side Effects
- New Drug Combo Effective Against Treatment-Resistant IBD, Trials Show
- New Warning Labels Might Help People Cut Back On Drinking
- Ozempic Can Curb Cravings in Alcohol Use Disorder, Landmark Trial Finds
- US on the Brink of Losing Measles-free Status, Study Warns
- Delays in Visa Program Threaten Doctor Placements in Underserved Areas
Many long COVID sufferers feel that their real problems were ignored while public health went ape over COVID counts, transmission rates, and enforcing masks and vaccines.
This New York Times report of serotonin-implicated research may finally help advance solutions for memory loss and other real problems of COVID.
Scientists Offer a New Explanation for Long Covid
Oct. 16, 2023
The News
A team of scientists is proposing a new explanation for some cases of long Covid, based on their findings that serotonin levels were lower in people with the complex condition.
In their study, published on Monday in the journal Cell, researchers at the University of Pennsylvania suggest that serotonin reduction is triggered by remnants of the virus lingering in the gut. Depleted serotonin could especially explain memory problems and some neurological and cognitive symptoms of long Covid, they say.
Why It Matters: New ways to diagnose and treat long Covid.
This is one of several new studies documenting distinct biological changes in the bodies of people with long Covid — offering important discoveries for a condition that takes many forms and often does not register on standard diagnostic tools like X-rays.
The research could point the way toward possible treatments, including medications that boost serotonin. And the authors said the biological pathway that their research outlines could unite many of the major theories of what causes long Covid: lingering remnants of the virus, inflammation, increased blood clotting and dysfunction of the autonomic nervous system.
“All these different hypotheses might be connected through the serotonin pathway,” said Christoph Thaiss, a lead author of the study and an assistant professor of microbiology at the Perelman School of Medicine at the University of Pennsylvania.
“Second of all, even if not everybody experiences difficulties in the serotonin pathway, at least a subset might respond to therapies that activate this pathway,” he said.
“This is an excellent study that identifies lower levels of circulating serotonin as a mechanism for long Covid,” said Akiko Iwasaki, an immunologist at Yale University. Her team and colleagues at the Icahn School of Medicine at Mount Sinai recently published a study that identified other biological changes linked to some cases of long Covid, including levels of the hormone cortisol. These studies could point to specific subtypes of long Covid or different biological indicators at different points in the condition.
The Back Story: A series of disruptions set off by bits of virus in the gut.
Researchers analyzed the blood of 58 patients who had been experiencing long Covid for between three months and 22 months since their infection. Those results were compared to blood analysis of 30 people with no post-Covid symptoms and 60 patients who were in the early, acute stage of coronavirus infection.
Maayan Levy, a lead author and assistant professor of microbiology at the Perelman School of Medicine, said levels of serotonin and other metabolites were altered right after a coronavirus infection, something that also happens immediately after other viral infections.
But in people with long Covid, serotonin was the only significant molecule that did not recover to pre-infection levels, she said.
The team analyzed stool samples from some of the long Covid patients and found that they contained remaining viral particles. Putting the findings in patients together with research on mice and miniature models of the human gut, where most serotonin is produced, the team identified a pathway that could underlie some cases of long Covid.
Here’s the idea: Viral remnants prompt the immune system to produce infection-fighting proteins called interferons. Interferons cause inflammation that reduces the body’s ability to absorb tryptophan, an amino acid that helps produce serotonin in the gut. Blood clots that can form after a coronavirus infection may impair the body’s ability to circulate serotonin.
Depleted serotonin disrupts the vagus nerve system, which transmits signals between the body and the brain, the researchers said. Serotonin plays a role in short-term memory, and the researchers proposed that depleted serotonin could lead to memory problems and other cognitive issues that many people with long Covid experience.
“They showed that one-two-three punch to the serotonin pathway then leads to vagal nerve dysfunction and memory impairment,” Dr. Iwasaki said.
There are caveats. The study was not large, so the findings need to be confirmed with other research. Participants in some other long Covid studies, in which some patients had milder symptoms, did not always show depleted serotonin, a result that Dr. Levy said might indicate that depletion happened only in people whose long Covid involves multiple serious symptoms.
What’s Next: A clinical trial of Prozac.
Scientists want to find biomarkers for long Covid — biological changes that can be measured to help diagnose the condition. Dr. Thaiss said the new study suggested three: the presence of viral remnants in stool, low serotonin and high levels of interferons.
Most experts believe that there will not be a single biomarker for the condition, but that several indicators will emerge and might vary, based on the type of symptoms and other factors.
There is tremendous need for effective ways to treat long Covid, and clinical trials of several treatments are underway. Dr. Levy and Dr. Thaiss said they would be starting a clinical trial to test fluoxetine, a selective serotonin reuptake inhibitor often marketed as Prozac, and possibly also tryptophan.
“If we supplement serotonin or prevent the degradation of serotonin, maybe we can restore some of the vagal signals and improve memory and cognition and so on,” Dr. Levy said.
https://www.nytimes.com/2023/10/16/health/long-covid-serotonin.html
Pam Belluck is a health and science writer whose honors include sharing a Pulitzer Prize and winning the Victor Cohn Prize for Excellence in Medical Science Reporting. She is the author of “Island Practice,” a book about an unusual doctor.
Ms. Belluck writes about a wide range of subjects, including the coronavirus pandemic, reproductive health, brain science, neurological disorders and mental health. Her work on Ebola with six colleagues won the 2015 Pulitzer Prize for international reporting and other awards. Her project about surgery for women traumatized by genital cutting won a Nellie Bly Award for Best Front Page Story and other honors. Ms. Belluck’s reporting on the devastating effects of Covid was honored with a New York Press Club Award and a Newswomen’s Club Front Page Award. She contributed, along with many colleagues, to the Times’s pandemic coverage, which earned the paper a 2021 Pulitzer for public service. Ms. Belluck, along with a photographer and translator, also won a New York Press Club award for reporting in Brazil on babies harmed by the Zika virus.Ms. Belluck has reported on Alzheimer’s from mountain villages in Colombia, a California prison and dementia centers in South Korea, and she has investigated the controversial Alzheimer’s drug Aduhelm. Her two-part series Mother’s Mind helped spur efforts to detect and treat maternal depression. She also covers lighter topics, including the discovery of the world’s oldest leather shoe (size 7, right foot, preserved for 5,500 years in sheep dung), and her piece on a lost cat navigating 200 miles home inspired a children’s book.
Her work has been chosen for The Best American Science Writing and The Best American Sports Writing. She won a Fulbright Scholarship and a Knight Journalism Fellowship and was selected to be a Ferris Professor of Journalism at Princeton University. She is frequently invited to speak about her work and has served on advisory boards related to science communication.
Her book, “Island Practice,” about a colorful and contrarian doctor whose patients have included Kennedys and a hermit in a vine igloo, is being considered for a TV series. In her spare time, Ms. Belluck is a jazz flutist.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.















